Breast cancer - one term, many entities? - PubMed (original) (raw)
Review
. 2011 Oct;121(10):3789-96.
doi: 10.1172/JCI57100. Epub 2011 Oct 3.
Affiliations
- PMID: 21965335
- PMCID: PMC3195465
- DOI: 10.1172/JCI57100
Review
Breast cancer - one term, many entities?
Nicholas R Bertos et al. J Clin Invest. 2011 Oct.
Abstract
Breast cancer, rather than constituting a monolithic entity, comprises heterogeneous tumors with different clinical characteristics, disease courses, and responses to specific treatments. Tumor-intrinsic features, including classical histological and immunopathological classifications as well as more recently described molecular subtypes, separate breast tumors into multiple groups. Tumor-extrinsic features, including microenvironmental configuration, also have prognostic significance and further expand the list of tumor-defining variables. A better understanding of the features underlying heterogeneity, as well as of the mechanisms and consequences of their interactions, is essential to improve targeting of existing therapies and to develop novel agents addressing specific combinations of features.
Figures
Figure 1. Schematic depiction of normal breast architecture and breast tumor and surrounding stroma, illustrating some of the tumor-intrinsic and microenvironmental variables contributing to disease heterogeneity.
(A) Normal breast architecture. (B) Breast tumor and surrounding stroma. TAM, tumor-associated macrophage.
Similar articles
- Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Brechbuhl HM, et al. Mol Carcinog. 2020 Oct;59(10):1129-1139. doi: 10.1002/mc.23242. Epub 2020 Aug 21. Mol Carcinog. 2020. PMID: 32822091 Free PMC article. - Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X, Ma F, Liu S, Wu S, Xiao R, Yuan L, Sun X, Yi Z, Yang H, Xu B. Guan X, et al. Oncotarget. 2016 Oct 4;7(40):65993-66002. doi: 10.18632/oncotarget.11787. Oncotarget. 2016. PMID: 27602758 Free PMC article. - Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS. Ibrahim E, et al. Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26. Med Oncol. 2009. PMID: 19034706 - Triple-negative breast cancer: current state of the art.
Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S. Rastelli F, et al. Tumori. 2010 Nov-Dec;96(6):875-88. Tumori. 2010. PMID: 21388048 Review. - MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Andorfer CA, Necela BM, Thompson EA, Perez EA. Andorfer CA, et al. Trends Mol Med. 2011 Jun;17(6):313-9. doi: 10.1016/j.molmed.2011.01.006. Epub 2011 Mar 2. Trends Mol Med. 2011. PMID: 21376668 Review.
Cited by
- A retrospective cohort study to evaluate disease burden, health care resource utilization, and costs in patients with breast cancer in Dubai, UAE.
Hamza D, Zayed M, Tahoun N, Farghaly M, Kumaresan S, Ramachandrachar BC, Ali A. Hamza D, et al. BMC Health Serv Res. 2024 Jul 12;24(1):810. doi: 10.1186/s12913-024-11193-8. BMC Health Serv Res. 2024. PMID: 38997691 Free PMC article. - Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges.
Lehmann U. Lehmann U. Cancers (Basel). 2024 Jun 7;16(12):2164. doi: 10.3390/cancers16122164. Cancers (Basel). 2024. PMID: 38927870 Free PMC article. Review. - Educational level and characteristics of invasive breast cancer: findings from a French prospective cohort.
Berger E, Gelot A, Fournier A, Dossus L, Boutron-Ruault MC, Severi G, Castagné R, Delpierre C. Berger E, et al. Cancer Causes Control. 2024 Aug;35(8):1151-1163. doi: 10.1007/s10552-024-01873-5. Epub 2024 Apr 14. Cancer Causes Control. 2024. PMID: 38615276 - The TGFβ2-Snail1-miRNATGFβ2 Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer.
Luo L, Xu N, Fan W, Wu Y, Chen P, Li Z, He Z, Liu H, Lin Y, Zheng G. Luo L, et al. Clin Transl Med. 2024 Feb;14(2):e1558. doi: 10.1002/ctm2.1558. Clin Transl Med. 2024. PMID: 38299307 Free PMC article. - The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity.
Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, Morellato A, Ala U, Taverna D, Turco E, Defilippi P. Salemme V, et al. Front Oncol. 2023 May 17;13:1170264. doi: 10.3389/fonc.2023.1170264. eCollection 2023. Front Oncol. 2023. PMID: 37265795 Free PMC article. Review.
References
- Pedersen L, Zedeler K, Holck S, Schiodt T, Mouridsen HT. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer. 1995;31A(13–14):2289–2295. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous